Balyasny Asset Management
KALA icon

Balyasny Asset Management’s KALA BIO KALA Stock Holding History

Balyasny Asset Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6
Closed -$233K – 1961
2018
Q1 		$233K Buy
6
+2
+50% +$75.9K ﹤0.01% 1712
2017
Q4 		$206K Buy
+4
New +$187K ﹤0.01% 1895

Other funds holding KALA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management's KALA Position: Q2 2018 in Review

Balyasny Asset Management sold out of KALA BIO (KALA) in Q2 2018, closing a stake of 6 shares — an estimated $233K sold.

Balyasny Asset Management first reported a position in KALA in Q4 2017 and held it in 2 quarters. The position peaked at $233K in Q1 2018. 54 funds tracked by Wall St. Rank hold KALA as of Q2 2018.

  • Balyasny Asset Management reported no remaining KALA BIO position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 6 KALA BIO shares in Q2 2018, an estimated $233K.
  • Balyasny Asset Management first reported a position in KALA BIO in Q4 2017 and held it in 2 quarters.
  • Balyasny Asset Management's KALA BIO position peaked at $233K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held KALA BIO as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.